Breast cancer detection by B7-H3-targeted ultrasound molecular imaging

Cancer Research

Volumn 75, Issue 12, 2015, Pages 2501-2509

  Bachawal, Sunitha V ^a   Jensen, Kristin C ^a,b   Wilson, Katheryne E ^a   Tian, Lu ^c   Lutz, Amelie M ^a   Willmann, Jürgen K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 H3 ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN; CD276 PROTEIN, MOUSE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST TUMOR; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ECHOMAMMOGRAPHY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROBUBBLE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; DIAGNOSTIC IMAGING; DISEASE MODEL; ECHOGRAPHY; FEMALE; METABOLISM; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; UDDER; VASCULARIZATION;

ANIMALS; B7 ANTIGENS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; MOLECULAR IMAGING; ULTRASONOGRAPHY;

EID: 84942883858     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3361     Document Type: Article

References (52)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk M, Saslow D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2014; 64: 30-51.
3. Wang AT, Vachon CM, Brandt KR, Ghosh K. Breast density and breast cancer risk: a practical review. Mayo Clin Proc 2014; 89: 548-57.
4. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012; 307: 1394-404.
5. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-36.
6. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225: 165-75.
7. Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD. Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. Am J Obstet Gynecol 2015; 212: 9-17.
8. Buchberger W, Niehoff A, Obrist P, DeKoekkoek-Doll P, Dunser M. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 2000; 21: 325-36.
9. Leconte I, Feger C, Galant C, Berliere M, Berg BV, D'Hoore W, et al. Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density. AJR Am J Roentgenol 2003; 180: 1675-9.
10. Kaplan SS Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 2001; 221: 641-9.
11. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299: 2151-63.
12. Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. Radiology 2012; 265: 59-69.
13. Weinstein SP, Localio AR, Conant EF, Rosen M, Thomas KM, Schnall MD. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 2009; 27: 6124-8.
14. Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med 2012; 53: 345-8.
15. Foygel K, Wang H, Machtaler S, Lutz AM, Chen R, Pysz M, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology 2013; 145: 885-94 e3.
16. Bachawal SV, Jensen KC, Lutz AM, Gambhir SS, Tranquart F, Tian L, et al. Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model. Cancer Res 2013; 73: 1689-98.
17. Wen Q, Wan S, Liu Z, Xu S, Wang H, Yang B. Ultrasound contrast agents and ultrasound molecular imaging. J Nanosci Nanotechnol 2014; 14: 190-209.
18. Kiessling F, Fokong S, Bzyl J, Lederle W, Palmowski M, Lammers T. Recent advances in molecular, multimodal and theranostic ultrasound imaging. Adv Drug Deliv Rev 2014; 72: 15-27.
19. Bzyl J, Lederle W, Rix A, Grouls C, Tardy I, Pochon S, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol 2011; 21: 1988-95.
20. Roesli C, Neri D. Methods for the identification of vascular markers in health and disease: from the bench to the clinic. J Proteomics 2010; 73: 2219-29.
21. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, StCroix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-54.
22. Turtoi A, Dumont B, Greffe Y, Blomme A, Mazzucchelli G, Delvenne P, et al. Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues. J Proteome Res 2011; 10: 3160-82.
23. Chandler I, Houlston R, Landberg G. A practical guide to constructing and using tissue microarrays. Methods Mol Biol 2011; 675: 363-73.
24. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009; 9: 463.
25. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-80.
26. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle Toncogene: a transgenic mousemodel for metastatic disease. Mol Cell Biol 1992; 12: 954-61.
27. Pochon S, Tardy I, Bussat P, Bettinger T, Brochot J, von Wronski M, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010; 45: 89-95.
28. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163: 2113-26.
29. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz AM, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246: 508-18.
30. Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts. Clin Imaging 2013; 37: 480-6.
31. Pysz MA, Machtaler SB, Seeley ES, Lee JJ, Brentnall TA, Rosenberg J, et al. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. Radiology 2015; 274: 790-9.
32. Lutz AM, Bachawal SV, Drescher CW, Pysz MA, Willmann JK, Gambhir SS. Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res 2014; 20: 1313-22.
33. Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: friend or foe? Int J Cancer 2014; 134: 2764-71.
34. Vigdorovich V, Ramagopal UA, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure 2013; 21: 707-17.
35. Dai W, Shen G, Qiu J, Zhao X, Gao Q. Aberrant expression of B7-H3 in gastric adenocarcinoma promotes cancer cell metastasis. Oncol Rep 2014; 32: 2086-92.
36. Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med 2013; 31: 283-91.
37. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008; 14: 5150-7.
38. Wang F, Wang G, Liu T, Yu G, Zhang G, Luan X. B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. Cancer Invest 2014; 32: 262-71.
39. Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE 2013; 8: e70689.
40. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007; 67: 7893-900.
41. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-12.
42. Brunner A, Hinterholzer S, Riss P, Heinze G, Brustmann H. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 2012; 124: 105-11.
43. Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, et al. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survivalin breast cancer patients. Ann Surg Oncol 2014; 21 Suppl 4: S546-54.
44. Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG, Huang JA. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res 2013; 319: 96-102.
45. Hu Y, Lv X, Wu Y, Xu J, Wang L, Chen W, et al. Expression of costimulatory molecule B7-H3 and its prognostic implications inhuman acute leukemia. Hematology 2015; 20: 187-95.
46. Bin Z, Guangbo Z, Yan G, Huan Z, Desheng L, Xueguang Z. Over-expression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients. J Surg Res 2014; 188: 396-403.
47. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010; 252: 1044-51.
48. Nygren MK, Tekle C, Ingebrigtsen VA, Fodstad O. B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Front Biosci 2011; 3: 989-93.
49. Loos M, Hedderich DM, Friess H, Kleeff J. B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010; 2010: 683875.
50. Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006; 12: 457-9.
51. Liu C, Liu J, Wang J, Liu Y, Zhang F, Lin W, et al. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10. Mol Med Rep 2013; 7: 134-8.
52. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256: 519-27.